262 related articles for article (PubMed ID: 26699426)
1. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method.
Corbet C; Ragelle H; Pourcelle V; Vanvarenberg K; Marchand-Brynaert J; Préat V; Feron O
J Control Release; 2016 Feb; 223():53-63. PubMed ID: 26699426
[TBL] [Abstract][Full Text] [Related]
2. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight.
Ragelle H; Colombo S; Pourcelle V; Vanvarenberg K; Vandermeulen G; Bouzin C; Marchand-Brynaert J; Feron O; Foged C; Préat V
J Control Release; 2015 Aug; 211():1-9. PubMed ID: 25989603
[TBL] [Abstract][Full Text] [Related]
3. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
4. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
[TBL] [Abstract][Full Text] [Related]
5. Targeted gene silencing using RGD-labeled chitosan nanoparticles.
Han HD; Mangala LS; Lee JW; Shahzad MM; Kim HS; Shen D; Nam EJ; Mora EM; Stone RL; Lu C; Lee SJ; Roh JW; Nick AM; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2010 Aug; 16(15):3910-22. PubMed ID: 20538762
[TBL] [Abstract][Full Text] [Related]
6. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
7. Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.
Müller K; Kessel E; Klein PM; Höhn M; Wagner E
Mol Pharm; 2016 Jul; 13(7):2332-45. PubMed ID: 27177200
[TBL] [Abstract][Full Text] [Related]
8. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
10. Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity.
Guţoaia A; Schuster L; Margutti S; Laufer S; Schlosshauer B; Krastev R; Stoll D; Hartmann H
Carbohydr Polym; 2016 Jun; 143():25-34. PubMed ID: 27083340
[TBL] [Abstract][Full Text] [Related]
11. Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery.
Lee JH; Ku SH; Kim MJ; Lee SJ; Kim HC; Kim K; Kim SH; Kwon IC
J Control Release; 2017 Oct; 263():29-38. PubMed ID: 28373128
[TBL] [Abstract][Full Text] [Related]
12. Chitosan Nanoparticles for SiRNA Delivery In Vitro.
Ragelle H; Vanvarenberg K; Vandermeulen G; Préat V
Methods Mol Biol; 2016; 1364():143-50. PubMed ID: 26472448
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of Fe
Arami S; Rashidi MR; Mahdavi M; Fathi M; Entezami AA
Hum Exp Toxicol; 2017 Mar; 36(3):227-237. PubMed ID: 27162247
[TBL] [Abstract][Full Text] [Related]
14. PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo.
Aldrian G; Vaissière A; Konate K; Seisel Q; Vivès E; Fernandez F; Viguier V; Genevois C; Couillaud F; Démèné H; Aggad D; Covinhes A; Barrère-Lemaire S; Deshayes S; Boisguerin P
J Control Release; 2017 Jun; 256():79-91. PubMed ID: 28411182
[TBL] [Abstract][Full Text] [Related]
15. Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.
Salimifard S; Karoon Kiani F; Sadat Eshaghi F; Izadi S; Shahdadnejad K; Masjedi A; Heydari M; Ahmadi A; Hojjat-Farsangi M; Hassannia H; Mohammadi H; Boroumand-Noughabi S; Keramati MR; Jadidi-Niaragh F
Life Sci; 2020 Nov; 260():118423. PubMed ID: 32941896
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles.
Rudzinski WE; Palacios A; Ahmed A; Lane MA; Aminabhavi TM
Carbohydr Polym; 2016 Aug; 147():323-332. PubMed ID: 27178938
[TBL] [Abstract][Full Text] [Related]
17. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
18. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
19. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating.
Jagani HV; Josyula VR; Palanimuthu VR; Hariharapura RC; Gang SS
Eur J Pharm Sci; 2013 Mar; 48(4-5):611-8. PubMed ID: 23291045
[TBL] [Abstract][Full Text] [Related]
20. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing.
Malmo J; Sørgård H; Vårum KM; Strand SP
J Control Release; 2012 Mar; 158(2):261-8. PubMed ID: 22119955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
